Difference between revisions of "Comment Resolutions"
Jump to navigation
Jump to search
Line 62: | Line 62: | ||
|- | |- | ||
| [[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]] | | [[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]] | ||
+ | | Public Comment | ||
+ | | n/a | ||
+ | | No public comment for v2.0; it is an update of v1.0 | ||
+ | |- | ||
+ | | SPECT Ioflupane in Neurodegenerative Disease v1.1 | ||
| Public Comment | | Public Comment | ||
| 12.31.2016 | | 12.31.2016 | ||
− | | | + | | [[Media: SPECT Profile Response to Public Comments.v2017 06 06.xlsx | Public Comment Resolutions 2017-06-06]] |
|- | |- | ||
| [[Media:QIBA_99mTC SPECT 2020-05-12.pdf| 99mTC SPECT 2020-05-12]] | | [[Media:QIBA_99mTC SPECT 2020-05-12.pdf| 99mTC SPECT 2020-05-12]] |
Revision as of 23:46, 16 June 2020
Comments received during Public Comment, Technical Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee.
Per the QIBA Process, committees record how each collected comment was resolved and those resolutions are posted here.